Objectives: To investigate the up-regulation of chemokine ligand 20 (CCL20) in chronic rhinosinusitis mucosa and to localize the distribution of CCL20 in the human paranasal sinus mucosa.
Design: Prospective study.
Setting: Tertiary academic institution.
Patients: Ten patients who underwent functional endoscopic sinus surgery for chronic rhinosinusitis without nasal polyps and 10 normal control subjects.
Interventions: Messenger RNA was extracted from the sinus mucosa, and semiquantitative reverse transcriptase-polymerase chain reaction was performed. Immunohistochemical staining was used to localize the CCL20 protein.
Results: The expression levels of CCL20 messenger RNA level in chronic rhinosinusitis without nasal polyps were significantly increased compared with those in normal sinus mucosa. The expression of CCL20 protein was greater in chronic rhinosinusitis without nasal polyps mucosa and was localized to the epithelial and submucosal glandular cells.
Conclusion: CCL20 is an inducible product of human paranasal sinus epithelium that may play a role in modulating mucosal immunity of the sinus mucosa.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1001/archotol.132.5.537 | DOI Listing |
J Mycol Med
January 2025
Aix-Marseille Université, SSA, AP-HM, RITMES, Marseille, France; IHU-Méditerranée Infection, Marseille, France.
Fungal rhinosinusal infections comprise several nosological entities, including sinus fungus ball. Diagnosis of sinus fungus ball relies on patient interrogation and clinical and paraclinical findings. Mold species commonly involved include Aspergillus, as well as dematiaceous fungi.
View Article and Find Full Text PDFExpert Rev Clin Immunol
January 2025
Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous disease. High proportions of patients with CRSwNP characterized by type 2 inflammation fail to gain adequate control with conventional medical and surgical approaches. The application of biologics in clinical practice and assessments of novel biologics in clinical trials are blooming in expectations to fulfill the unmet medical needs of patients with CRSwNP with type 2 inflammation.
View Article and Find Full Text PDFPathogens
December 2024
Department of Otolaryngology and Laryngological Oncology, Poznań University of Medical Sciences, Przybyszewskiego 49 St., 60-355 Poznań, Poland.
Chronic rhinosinusitis (CRS) is a common inflammatory disease of the paranasal sinuses with a yet unknown etiology. As studies continue to elucidate the disease's heterogeneity inflammatory profile and presentation, there is a growing interest in the influence of the nasal microbiome on disease pathogenesis and chronicity. The sinus microbiota appear dominated by the and genera; known upper airway pathogens, such as , are present in the upper airways of healthy individuals, though at relatively lower abundances than in CRS patients.
View Article and Find Full Text PDFInt J Mol Sci
January 2025
Infectious Diseases Translational Research Program, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117545, Singapore.
Studies have indicated the potential importance of the human nasal and respiratory microbiomes in health and disease. However, the roles of these microbiomes in the pathogenesis of influenza and its complications are not fully understood. Therefore, the objective of this systematic review and analysis is to identify the patterns of nasal and respiratory microbiome dysbiosis and to define the unique signature bacteria associated with influenza compared with other respiratory tract infections.
View Article and Find Full Text PDFAllergol Int
January 2025
Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Background: Although randomized controlled trials (RCT) have demonstrated the efficacy of mepolizumab for asthma, they have excluded certain patient subgroups. To bridge the gap between RCT and real-world practice, the effectiveness of mepolizumab in a diverse population, including those potentially excluded from RCT, was assessed. Its effects on imaging findings and symptoms of chronic rhinosinusitis (CRS) with asthma were also assessed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!